Critisense

CritiSense, founded in 2004 by Avraham Mayevsky, operated from Giv'at Shmuel, Israel as a medical technology company. The firm focused on developing technology for the real-time monitoring of a patient's metabolic state, which could also serve as an endpoint for resuscitation efforts. Reports indicate the company is now deadpooled after having raised $2.2M in funding.

The company's primary product was the CritiView, a patient monitoring system designed to provide continuous, real-time data on a patient's condition. This system worked by sensing four physiological parameters at the tissue level to reflect the overall systemic metabolic state. The technology aimed to monitor mitochondrial function, microcirculatory blood flow, and oxygen saturation, providing data at both the tissue and cellular levels. A key benefit of the CritiView monitor was its ability to offer early identification of metabolic imbalances or issues with tissue viability, often in advance of what standard critical-care monitors could detect.

CritiView was positioned as an adjunctive monitor, meaning it was intended to be used alongside other standard medical monitoring equipment. By providing earlier warnings about changes at the tissue level, the device was designed to empower clinicians to take more precise and timely corrective actions. The business operated in the medical device market, specifically within the patient monitoring segment.

Keywords: patient monitoring, metabolic state, resuscitation endpoint, tissue viability, physiological parameters, medical device, mitochondrial function, microcirculatory blood flow, oxygen saturation, critical care, Avraham Mayevsky, CritiView, real-time monitoring